Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer,...
PDCO vs. CNMD: Which Stock Is the Better Value Option?
CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2022 to all shareholders of record as of September...
CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.
CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held Biorez, Inc.
PDCO vs. CNMD: Which Stock Is the Better Value Option?
CONMED Corporation (NYSE: CNMD) today announced a definitive agreement to acquire privately held Biorez, Inc. (Biorez), on a cash-free, debt-free basis, for cash consideration of $85 million at closing,...
CONMED's (CNMD) adjusted second-quarter earnings reflect strong segmental performance. However, unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin....
Conmed (CNMD) delivered earnings and revenue surprises of 0% and 1.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
